EQT Life Sciences and Gimv Co-Lead €51M Series B in Exciva

EQT Life Sciences and LSP 7 Lead $56M Series D in Neuros Medical

July 9, 2025

Medical Devices

EQT Life Sciences, together with the LSP 7 fund and EQT Health Economics strategy, co-led a $56 million Series D financing in Neuros Medical to support U.S. commercialization of the Altius direct electrical nerve stimulation system for chronic post-amputation pain. Proceeds will fund scaling of commercial operations to expand access to the FDA‑approved, non‑opioid treatment for adult amputees.

EQT, Silver Lake and Nestlé Expand Partnership with €3.5bn Investment in IVC Evidensia

February 9, 2021

Veterinary

IVC Evidensia has secured an aggregated new investment of €3.5 billion that values the company at an enterprise value of approximately €12.3 billion. The expanded partnership includes a substantial reinvestment by EQT Private Equity, a new minority investment from Silver Lake, and an increased minority stake from Nestlé Purina PetCare EMENA to support digitalisation and further growth across IVC's network of clinics.

EQT Acquires LSP (Life Sciences Partners)

November 10, 2021

Financial Services

EQT AB has acquired LSP (Life Sciences Partners), a leading European life-sciences venture capital firm, in a transaction that creates a new EQT Life Sciences business line. The deal values the upfront consideration at EUR 450 million (25% cash / 75% EQT shares) with a EUR 25 million earn‑out paid on meeting fundraising targets (total consideration EUR 475 million at close); LSP's 34-person team and partners join EQT to strengthen its healthcare investing capabilities.

Ampersand Capital Partners Makes Growth Investment in VIVEbiotech

December 4, 2024

Biotechnology

Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.

IQ-EQ (Astorg-backed) Acquires Davy Global Fund Management

July 22, 2021

Financial Services

IQ-EQ, backed by private equity firm Astorg, has agreed to acquire Davy Global Fund Management (DGFM) from Davy Group, subject to regulatory approval, with completion expected by end of 2021. The deal brings DGFM’s fund management and Real Estate ManCo capabilities into IQ-EQ’s Irish business (DGFM will rebrand to IQ-EQ) and expands IQ-EQ’s fund administration, corporate administration and portfolio management scale in Ireland.

ELIQUENT Life Sciences Acquires Azzur Consulting

May 7, 2025

Healthcare Services

ELIQUENT Life Sciences, a GHO Capital‑backed global regulatory, quality, and safety consulting firm, has acquired Azzur Consulting to strengthen its validation engineering, CQV, and quality/compliance capabilities. The Azzur team will integrate into ELIQUENT's global delivery organization to expand technical delivery across North America, Europe, Japan and other markets.